Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 0228-2890

20 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 0228-2890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

1 (Image 4)
Chemical structure diagram of duloxetine hydrochloride, showing its molecular framework including a thiophene ring, naphthyl group, and methylamine group bonded to hydrochloride.*
FDA Label Image

Figure1 (Image 5)

Figure1 (Image 5)
Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine delayed-release capsules treatment groups. The graph shows time from randomization on the x-axis and proportion of patients with relapse on the y-axis, illustrating lower relapse proportion with Duloxetine compared to placebo over the study period.*
FDA Label Image

Figure2 (Image 6)

Figure2 (Image 6)
A Kaplan-Meier plot depicting the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine delayed-release capsules. The graph shows treatment groups with placebo indicated by a dashed line and duloxetine by a solid line, illustrating differences in relapse rates across approximately 300 days.*
FDA Label Image

Figure3 (Image 7)

Figure3 (Image 7)
A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. Four lines represent different groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The y-axis shows percentage of patients improved, and the x-axis shows percent improvement in pain from baseline.*
FDA Label Image

Figure4 (Image 8)

Figure4 (Image 8)
A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends of patient improvement across increasing pain relief percentages.*
FDA Label Image

Figure5 (Image 9)

Figure5 (Image 9)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, once daily, and placebo. The vertical axis shows percentage of patients improved, while the horizontal axis shows percent pain improvement, illustrating treatment effects over different pain improvement levels.*
FDA Label Image

Figure6 (Image 10)

Figure6 (Image 10)
Line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily with placebo, with the percentage of patients improved decreasing as the percent improvement in pain increases.*
FDA Label Image

Figure 7 (Image 11)

Figure 7 (Image 11)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine delayed-release 60/120 mg once daily. The graph shows two lines: one with diamonds representing Duloxetine patients and another with crosses representing placebo patients, illustrating patient response distribution across different pain improvement thresholds.*
FDA Label Image

Figure8 (Image 12)

Figure8 (Image 12)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine Delayed-Release 60 mg once daily with placebo across various pain improvement thresholds. Duloxetine shows a higher percentage of patients improved relative to placebo at most improvement levels.*
FDA Label Image

Figure9 (Image 13)

Figure9 (Image 13)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine delayed-release 60/120 mg once daily. The graph shows two lines, one for placebo and one for Duloxetine, indicating patient outcomes at various pain improvement thresholds.*
FDA Label Image

Figure10 (Image 14)

FDA Label Image

1 (Image 15)

FDA Label Image

1 (Image 16)

FDA Label Image

1 (Image 17)

1 (Image 17)
Label for Duloxetine Delayed-Release Capsules, USP 20 mg, showing a package containing 60 capsules. The label includes dosage form as delayed-release capsules and highlights pharmacist instructions to dispense the accompanying medication guide. It also features storage instructions, manufacturing details by Teva Pharmaceuticals, and barcodes.*
FDA Label Image

Label 20 mg, 60 Capsules (Image 18)

Label 20 mg, 60 Capsules (Image 18)
Label for Duloxetine Delayed-Release Capsules USP, 30 mg strength, in a package of 30 capsules. The label includes dosage and storage instructions, a note to dispense the accompanying Medication Guide, and mentions the manufacturer as Teva Pharmaceuticals, Parsippany, NJ. The label features the NDC number 0228-2891-03 and a barcode.*
FDA Label Image

Label 30 mg, 30 Capsules (Image 19)

Label 30 mg, 30 Capsules (Image 19)
Label for Duloxetine Delayed-Release Capsules USP, 60 mg strength, in a package of 30 capsules. The label includes dosage instructions, storage conditions, and manufacturer information for Teva Pharmaceuticals, Parsippany, NJ. It features the Teva logo and a barcode with serialization coding area.*
FDA Label Image

Label 60 mg, 30 Capsules (Image 20)

Label 60 mg, 30 Capsules (Image 20)
Packaging label for Duloxetine Delayed-Release Capsules, USP, 60 mg, containing 30 capsules. The label shows that each capsule contains 57.3 mg of duloxetine hydrochloride, USP equivalent to 60 mg duloxetine. It includes instructions for pharmacists to dispense accompanying medication guides, storage conditions, manufacturing and labeler information from Actavis Pharma, Inc. under the Teva brand.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.